GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in ASCVD A Propensity Score-Matched Cohort Study

Objective: To evaluate whether GLP-1 RA use added to statins is associated with lower all-cause mortality, myocardial infarction (MI), and ischemic stroke versus statin monotherapy in ASCVD patients with body mass index (BMI) 30 kg/m2. Approach and Results:Using the TriNetX Research Network (108 U.S. healthcare organizations), we identified ASCVD patients with BMI 30 kg/m2 on statins initiating a GLP-1 RA (n=166,278) versus statin-only controls (n=920,176). Propensity score matching on 34 covariates yielded 119,911 matched pairs followed 3 years. Prespecified analyses included a BMI 35 subgrou

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.